Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases

Table 2

TPE indications and TPE replacement solutions.

TPE indications	TPE replacement solution, n (%)				Total, n=66
	Albumin 5%, n=39	Albumin 5% plus Fresh frozen plasma, n=8	4% succinylated gelatin, n=10	Fresh frozen plasma, n=9
DAH	8 (20.51)	7 (87.5)	3 (30)	2 (22.22)	20 (30.3)
Neuropsychiatric SLE	5 (12.81)	1 (12.5)	2 (20)	1 (11.11)	9 (13.6)
Rapidly progressive glomerulonephritis	6 (15.38)	0 (0)	1 (10)	0 (0)	7 (10.6)
Thrombotic microangiopathy	1 (2.56)	0 (0)	1 (10)	3 (33.33)	5 (7.6)
CAPS	3 (7.69)	0 (0)	0 (0)	2 (22.22)	5 (7.6)
Lupus nephritis (WHO Class IV)	2 (5.13)	0 (0)	1 (10)	1 (11.11)	4 (6.1)
Severe skin lupus	2 (5.13)	0 (0)	1 (10)	0 (0)	3 (4.5)
Inflammatory myopathies	3 (7.69)	0 (0)	0 (0)	0 (0)	3 (4.5)
Gastrointestinal lupus	1 (2.56)	0 (0)	0 (0)	0 (0)	1 (1.5)
Severe scleroderma	1 (2.56)	0 (0)	0 (0)	0 (0)	1 (1.5)
Severe SLE	1 (2.56)	0 (0)	0 (0)	0 (0)	1 (1.5)
Autoimmune meningoencephalitis	1 (2.56)	0 (0)	0 (0)	0 (0)	1 (1.5)
Neuromyelitis Optical	1 (2.56)	0 (0)	0 (0)	0 (0)	1 (1.5)
Rejection of the kidney allograft	1 (2.56)	0 (0)	0 (0)	0 (0)	1 (1.5)
Type B insulin resistance	1 (2.56)	0 (0)	0 (0)	0 (0)	1 (1.5)
Evans syndrome	1 (2.56)	0 (0)	0 (0)	0 (0)	1 (1.5)
Legs vasculitis	0 (0)	0 (0)	1 (10)	0 (0)	1 (1.5)
CNS Vasculitis	1 (2.56)	0 (0)	0 (0)	0 (0)	1 (1.5)

TPE: therapeutic plasma exchange; DAH: diffuse alveolar hemorrhage; SLE: systemic lupus erythematosus; CAPS: catastrophic antiphospholipid syndrome; WHO: World Health Organization; CNS: central nervous system.